NCT06506955 2026-03-11
Futibatinib in Patients Previously Enrolled in an Antecedent Futibatinib as Monotherapy or Combination Therapy.
Taiho Oncology, Inc.
Phase 2/3 Enrolling by invitation
Clinical Trials
6 trialsNCT05374590 2026-02-02
ADAPT Jr +
argenx
Phase 2/3 Enrolling by invitation
NCT06755515 2025-01-01
A Phase Ⅱ/Ⅲ Study of Rulonilimab Plus Chemotherapy± Bevacizumab for the First-Line Treatment of Persistent, Recurrent or Metastatic Cervical Cancer
Shandong New Time Pharmaceutical Co., LTD
Phase 2/3 Enrolling by invitation
NCT06306274 2024-12-02
Topical Tacrolimus for Breast Cancer-related Lymphedema
Odense University Hospital
Phase 2/3 Enrolling by invitation
NCT06544109 2024-08-09
Ven APL
The First Affiliated Hospital of Soochow University
Phase 2/3 Enrolling by invitation
NCT03459820 2023-11-27
Prostate Cancer Patient Management With 18F-DCFPyL PET/CT
Sir Mortimer B. Davis - Jewish General Hospital
Phase 2/3 Enrolling by invitation